Jessica Williamson
Adult Health · Wyndmoor, PANPI 1689071334
Payments from drug & device makers
Across 85 payments — averaging $33.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$628
- Amgen$361
- Calliditas Therapeutics US Inc.$359
- Ardelyx, Inc.$297
- Novo Nordisk$169
- Travere Therapeutics, Inc.$167
- plus $866 from 12 others
What the payments were for
- Food & beverage$2,845100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $628 |
| Amgen | 12 | $361 |
| Calliditas Therapeutics US Inc. | 6 | $359 |
| Ardelyx, Inc. | 10 | $297 |
| Novo Nordisk | 3 | $169 |
| Travere Therapeutics, Inc. | 4 | $167 |
| Lilly USA, LLC | 6 | $161 |
| Vifor Pharma, Inc. | 2 | $140 |
| Novartis | 5 | $119 |
| Fresenius USA Marketing, Inc. | 5 | $109 |
| Aurinia Pharma U.S., Inc. | 4 | $106 |
| Bayer | 4 | $77 |
| Akebia Therapeutics Inc | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 1 | $33 |
| Boehringer Ingelheim | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| OPKO Pharmaceuticals, LLC | 1 | $19 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,847 in reported general payments places this provider in the 85th percentile of 899 adult health providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 107 | $73,729 |
| VelphoroSucroferric Oxyhydroxide | 28 | $59,775 |
| AuryxiaFerric Citrate | 23 | $49,685 |
| JardianceEmpagliflozin | 24 | $16,174 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $14,816 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $13,784 |
| Sevelamer Carbonate | 60 | $9,920 |
| Cinacalcet Hcl | 29 | $7,262 |
| Nifedipine ErNifedipine | 140 | $5,335 |
| Clonidine | 19 | $2,414 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,103 |
| Losartan Potassium | 144 | $1,848 |
| Midodrine Hcl | 12 | $1,523 |
| Hydralazine Hcl | 51 | $1,352 |
| Atorvastatin Calcium | 77 | $1,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $628 | $87,513119 claims |
| Fresenius USA Marketing, Inc.Velphoro | $109 | $59,77528 claims |
| Akebia Therapeutics IncAuryxia | $41 | $49,68523 claims |
| Boehringer IngelheimJardiance | $25 | $16,17424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Wyndmoor
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$413K
- Jennifer MondilloSchwenksville$396K
- Elizabeth FaustDouglassville$356K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Lauren MassimoPhiladelphia$139K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.